Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Location status: Recruiting
Location contact
Rachel Freedman, MD, MPH
CONTACT
Rachel Freedman, MD, MPH
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07123649
This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.
Interested in participating?
Request Info80 year and older
Female
Interventional
Phase 2
Boston, Massachusetts, 02115, United States
Location status: Recruiting
Rachel Freedman, MD, MPH
CONTACT
Rachel Freedman, MD, MPH
PRINCIPAL_INVESTIGATOR
This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.
A participant will be placed into one of two groups: Group A: Usual Care vs. Group B: SDM Toolkit according to the randomized placement of the assigned study clinician.
Study procedures include questionnaires and option interviews with study staff.
Participation in this research study is expected to last about 2 years.
It is expected about 52 clinicians and 312 participants will take part in this research study.
The National Institute on Aging is providing funding for this research study
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Participant Inclusion Criteria:
-≥ 12 months since most recent breast surgery to affected breast (e.g., breast reduction surgery on an unaffected breast within 12 months is ok)
Participant Exclusion Criteria:
Clinician Inclusion Criteria:
The SDM toolkit is designed to support discussions on the continuation of surveillance mammography. It provides evidence-based guidelines, communication strategies, and education materials to aid in personalized decision-making.
Other names: SDM Toolkit
Time frame: Assessed at 2 years post-enrollment.
Mammography Rate is defined as the proportion of participants that undergo mammography by 2 years post-enrollment.
Time frame: Assessed at 2 years post-enrollment.
Mammography Count is defined as the count of all mammograms each participant underwent during study follow-up.
Time frame: Annually through 2 years of follow-up post-enrollment.
Participant Knowledge Score will be defined as the proportion of correct knowledge questions (range: 0 to 1).
Time frame: Annually through 2 years of follow-up post-enrollment.
Participant Decisional Quality Score will be defined as the sum of response scores (range of 0-4), with each individual response scored 0 or 1. Higher scores indicate higher decisional quality.
Contact information is provided by the study sponsor or research team.
Dana-Farber Cancer Institute
Other
Acronym: I-MAMMO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04816006
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phoenix, Arizona, United States
View Trial DetailsNCT05625659
Breast Cancer, Breast Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT06954337
Breast Cancer, Breast Diseases
Basking Ridge, New Jersey, United States
View Trial DetailsNCT07340541
Breast Cancer, Breast Diseases
Baltimore, Maryland, United States
View Trial Details